Novo aims to shorten the “time-to-market” for new drugs by up to two-thirds using AI.
AI is being utilized in areas such as analyzing research data and drafting documents. The company’s unit in India plays a central role in this development, where the focus has shifted from mass recruitment to AI expertise and improving operational efficiency.
Novo Nordisk is aiming to slash the time it takes to bring new drugs to market by up to two-thirds using AI, a top executive said, as the Danish drugmaker looks to regain momentum in the booming obesity drugs market.
“Historically, from ‘last patient, last visit’ to first filing might have been a year and a half. What we’re able to do now by implementing AI is bring that time down by months,” John Dawber, managing director for global business services, told a Reuters summit on Friday.